Pharma trends that will shape 2026: Building a future-ready, patient-centric industry
As we move closer to 2026, the pharmaceutical ecosystem is undergoing a profound transformation driven by digital innovation,…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Anil Matai
Anil Matai, Director General of OPPI, on the Future of Indian Pharma: From Product Provider to…
Regulatory Watch: Anil Matai, Director General of OPPI
Panel Discussion: The patient of the future: Shaping pharma’s next big opportunity
The Pharma Leadership and Innovation Conclave 2025 hosted a thought-provoking panel discussion on ‘The Patient of the Future:…
Some gaps in Union Budget 2025, but positive policy-level clarifications: Anil Matai, OPPI
Anil Matai, Director General, OPPI observes that while some gaps remain, OPPI is committed to facilitating and partnering with the…
Association leaders share their expectations from Budget 2025-26
Union Budget 2025-2026 must prioritise innovation, ease of doing business, and policies that strengthen the life sciences…
Anil Matai reflects on 2024 as a pivotal year for India’s pharma sector
OPPI DG highlights government initiatives and industry efforts shaping a patient-centric, innovation-driven future
Upskilling and reskilling: Key to driving innovation in India’s pharma sector
A skilled workforce is critical to addressing the complexities of modern drug development and personalised medicine.
Bhushan Akshikar appointed OPPI President
Current President Suresh Pattathil, Managing Director and General Manager, AbbVie India passes the baton on to Bhushan Akshikar
DCGI waives off local trials for drugs approved in well-regulated markets
The countries on the list include the US, UK, Japan, Australia, Canada and the EU
Union Budget 2024-25 reflects a forward-looking and inclusive approach
Anil Matai, Director General, OPPI expressed that while positive strides were taken in the Union Budget 2024-25, the pharma sector…